I recently reread my own post in #msg-45522123 and I see that it has the smoking gun vis-à-vis Teva’s lame attempt to copy Lovenox. Here is the relevant passage, which is a direct quote from Bill Marth at the Goldman Sachs conference on 8-Jan-2010:
Bill, the “other stuff” in Lovenox that you speak of is not necessarily junk; to the contrary, it may have physiological activity that is not well understood.
If you have not characterized the Lovenox junk, then you have not replicated Lovenox and your drug is not the same as Lovenox. That’s why you have not gotten FDA approval even after eight years.
Sorry, Bill—your ItalFarmaco gambit may have been a reasonable thing to do in 2003, but it doesn’t cut it with the FDA and I think you know that already.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.